IDEXX Laboratories Inc
NASDAQ:IDXX
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
361.04
766.68
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one
IDXX
stock under the Base Case scenario is
309.08
USD.
Compared to the current market price of 688.48 USD,
IDEXX Laboratories Inc
is
Overvalued by 55%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.
Let our AI break down the key assumptions behind the intrinsic value calculation for IDEXX Laboratories Inc.
| US |
|
Abbott Laboratories
NYSE:ABT
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
|
| US |
|
GE Healthcare Technologies Inc
NASDAQ:GEHC
|
|
| US |
|
Resmed Inc
NYSE:RMD
|
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
IDEXX’s significant exposure to the companion animal diagnostics market leaves it vulnerable to heightened competition from emerging, lower-cost testing solutions, potentially eroding the firm’s premium pricing power and margins.
Aggressive R&D spending on new testing platforms may strain free cash flow if product launches fail to achieve the expected level of market adoption, especially as veterinarians remain cautious about adopting new technologies.
IDEXX’s reliance on distributor networks and veterinary practice consolidation could result in margin pressure if large corporate veterinary groups demand more favorable pricing or opt for alternative diagnostic providers.
IDEXX’s strong brand reputation and broad portfolio of proprietary diagnostic instruments and assays provide significant pricing power and high switching costs, allowing it to maintain above-average margins.
The company’s continued expansion into specialty diagnostics, including advanced molecular testing, positions IDEXX to capture new revenue streams as veterinary practices increasingly invest in more comprehensive diagnostic capabilities.
IDEXX’s global footprint, along with its robust software and analytics offerings, strengthens its competitive moat by delivering an integrated ecosystem of products and services that enhance veterinary workflow efficiency.
Revenue & Expenses Breakdown
IDEXX Laboratories Inc
Balance Sheet Decomposition
IDEXX Laboratories Inc
| Current Assets | 1.5B |
| Cash & Short-Term Investments | 208.2m |
| Receivables | 715m |
| Other Current Assets | 553.9m |
| Non-Current Assets | 1.9B |
| Long-Term Investments | 59.1m |
| PP&E | 867.6m |
| Intangibles | 528.4m |
| Other Non-Current Assets | 454.5m |
| Current Liabilities | 1.3B |
| Accounts Payable | 122.3m |
| Accrued Liabilities | 399.7m |
| Short-Term Debt | 455m |
| Other Current Liabilities | 274.9m |
| Non-Current Liabilities | 573.7m |
| Long-Term Debt | 374.8m |
| Other Non-Current Liabilities | 198.9m |
Free Cash Flow Analysis
IDEXX Laboratories Inc
| USD | |
| Free Cash Flow | USD |
Earnings Waterfall
IDEXX Laboratories Inc
|
Revenue
|
4.2B
USD
|
|
Cost of Revenue
|
-1.6B
USD
|
|
Gross Profit
|
2.6B
USD
|
|
Operating Expenses
|
-1.3B
USD
|
|
Operating Income
|
1.3B
USD
|
|
Other Expenses
|
-278.7m
USD
|
|
Net Income
|
1B
USD
|
IDXX Profitability Score
Profitability Due Diligence
IDEXX Laboratories Inc's profitability score is 72/100. The higher the profitability score, the more profitable the company is.
Score
IDEXX Laboratories Inc's profitability score is 72/100. The higher the profitability score, the more profitable the company is.
IDXX Solvency Score
Solvency Due Diligence
IDEXX Laboratories Inc's solvency score is 53/100. The higher the solvency score, the more solvent the company is.
Score
IDEXX Laboratories Inc's solvency score is 53/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
IDXX Price Targets Summary
IDEXX Laboratories Inc
According to Wall Street analysts, the average 1-year price target for
IDXX
is 783.52 USD
with a low forecast of 479.96 USD and a high forecast of 892.5 USD.
Dividends
Current shareholder yield for
IDXX is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
IDXX
stock under the Base Case scenario is
309.08
USD.
Compared to the current market price of 688.48 USD,
IDEXX Laboratories Inc
is
Overvalued by 55%.